US Orders Constellation to Keep Eddystone Units Running; Adds Near-Term Certainty but Raises Questions on Asset Flexibility

What happened

On May 21, the US Energy Secretary ordered Constellation Energy to maintain operations at two Eddystone generating units in Pennsylvania, a directive that provides near-term grid reliability but complicates the company's portfolio reshaping plans. This order comes as Constellation awaits a key FERC ruling on transferring capacity interconnection rights from Eddystone to its Crane restart project, with a June 1 deadline. The forced operational status of Eddystone may limit Constellation's ability to optimize its PJM footprint, particularly as it works to divest ~4.4 GW to LS Power by September. While the directive underscores the strategic importance of these units to grid stability, it also introduces regulatory friction that could delay or alter the Crane restart timeline. Overall, the development adds a layer of political risk to an already complex execution story, but does not fundamentally change the near-term catalysts or valuation framework.

Implication

Investors should monitor the interplay between this DOE directive and the pending FERC waiver decision: if the waiver is granted, Eddystone's extended life could be a bridge asset; if denied, the order effectively traps capital in an aging plant. The broader thesis that Constellation is a scarce nuclear winner remains intact, but the regulatory/political overlay adds execution risk that the current valuation (36x P/E) does not fully discount. Patience is warranted until the FERC order and PJM tariff clarity emerge.

Thesis delta

The order to keep Eddystone running tilts the regulatory pendulum toward reliability concerns over market flexibility, which could slow the Crane restart and divert management attention. Combined with ongoing divestiture deadlines, this reduces the probability of a near-term bull case (20% chance) and modestly increases bear-case probability. However, the core AI/data-center demand story and nuclear scarcity are unchanged, so the WAIT rating and entry point of $245 remain sensible.